You are here: Industry Insights > AT-527

News List

Atea to study AT-527 as monotherapy and in combination for Covid-19 Pharmaceutical-Technology
December 16, 2021
Atea Pharmaceuticals has announced an update to its strategy to use AT-527 as a single agent and in combination against the SARS-CoV-2 virus and the new variants.
Atea to terminate Covid-19 drug development deal with Roche Pharmaceutical-Technology
November 18, 2021
Atea Pharmaceuticals has announced plans to terminate a strategic partnership with Roche to co-develop the former’s experimental oral direct-acting antiviral pill, AT-527, to treat Covid-19.
Atea reports positive Phase I data from oral antiviral agent trial for Covid-19 pharmaceutical-technology
March 09, 2021
Atea Pharmaceuticals has reported that results from the Phase I study of oral antiviral agent AT-527 showed it was well tolerated with a favourable safety profile in healthy volunteers.
Roche, Atea Pharma to Develop Potential Oral COVID-19 Treatment contractpharma
October 23, 2020
Roche and Atea Pharmaceuticals, Inc. have partnered to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to treat COVID-19.